This site is intended for healthcare professionals only
LoginRegister

Diabetes and Endocrinology Dialogues

Thiazolidinedione may reduce CV events and adverse renal events in diabetic patients: Study

Thiazolidinedione may reduce CV events and adverse renal events in diabetic patients: Study

A new study published in the Journal of Clinical Endocrinology and Metabolism showed that among type 2 diabetes mellitus (T2DM) patients with AKD,...
View All

Latest News and Guidelines

SGLT2i Versus DPP-4i as an Add-On Therapy and the Risk of PAD-Related Surgical Events

Diabetes Drugs SGLT2i and GLP-1 RAs may Reduce Risk of Pneumonia and Sepsis, finds research

Association between atopic dermatitis with hyperparathyroidism

Atopic Dermatitis Linked to Higher Risk of Hyperparathyroidism, Independent of Vitamin D Levels:...

Pre-Pregnancy Obesity, Hypertension, and Stillbirth Risk

Obesity and Chronic Hypertension: Key Factors in Stillbirth and Perinatal Death Risk and Delivery...

Right Turn Show - Decoding the Use of Dapagliflozin and its Combinations with Metformin and Sitagliptin in Specialty Care Settings

Right Turn Show - Decoding the Use of Dapagliflozin and its Combinations with Metformin and...

Cutaneous carbonyl stress markers associated with nerve damage in recent-onset type 2 diabetes: Study

Cutaneous carbonyl stress markers associated with nerve damage in recent-onset type 2 diabetes:...

Intensive Glucose Lowering Reduces Vascular Events Across All Age Groups and Diabetes Durations

Intensive Glucose Lowering Cuts Vascular Risks for Diabetic Patients, Regardless of Age or Duration:...

View All
X